Please assess the completion status of the following clinical trial:

Trial Title: Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female subjects between 18 and 65 years of age, with a diagnosis of schizophrenia, as defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) criteria~2. Subjects who have been recently hospitalized or who would benefit from hospitalization for an acute relapse of schizophrenia~3. Subjects experiencing an acute exacerbation of psychotic symptoms~4. Other protocol specific inclusion criteria may apply~Exclusion Criteria:~1. Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving study drug~2. Subjects with a current DSM-IV-TR Axis I diagnosis of:~   * Schizoaffective disorder~  * Major depressive disorder (MDD)~  * Bipolar disorder~  * Delirium, dementia, amnestic or other cognitive disorder~  * Borderline, paranoid, histrionic, schizotypal, schizoid or antisocial personality disorder~3. Subjects presenting with a first episode of schizophrenia~4. Other protocol specific exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- OPC-34712 [Brexpiprazole] High Dose (Type: EXPERIMENTAL): Higher Dose, tablet, once daily, for six weeks
- OPC-34712 [Brexpiprazole] Middle Dose (Type: EXPERIMENTAL): Middle Dose, tablet, once daily, for six weeks
- OPC-34712 [Brexpiprazole] Low Dose (Type: EXPERIMENTAL): Lower Dose, tablet, once daily, for six weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, once daily, for six weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).